A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 360 participants.
Also called NCT01970046
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 360 participants
- Registry
-
NCT01970046
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01970046. Randomized; quadruple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2014-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Placebo/Metformin
- Intervention (Drug)
- SP2086 50 mg b.i.d/Metformin
- Intervention (Drug)
- SP2086 50 mg q.d./Metformin
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct01970046- Content hash
9b6e8059a2f1583f795f613e2ee3770e00248450f1c1b1c838e7997366bc51b9